Effects of antidiabetic drugs on glucose tolerance in streptozotocin- nicotinamide-induced mildly diabetic and streptozotocin-induced severely diabetic mice

Hormone and Metabolic Research

Volumn 40, Issue 12, 2008, Pages 880-886

  Tahara, A ^a   Matsuyama Yokono, A ^a   Nakano, R ^a   Someya, Y ^a   Shibasaki, M ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Diabetes; Glibenclamide; Glucose tolerance; Insulin; Metformin; Sitagliptin; Voglibose

Indexed keywords

GLIBENCLAMIDE; GLUCAGON LIKE PEPTIDE 1; INSULIN; METFORMIN; NICOTINAMIDE; SITAGLIPTIN; VOGLIBOSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLUCOSE URINE LEVEL; INSULIN LIKE ACTIVITY; INSULIN RELEASE; INSULIN TREATMENT; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STREPTOZOCIN DIABETES; TREATMENT OUTCOME; WEIGHT REDUCTION;

ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE INTOLERANCE; GLUCOSE TOLERANCE TEST; GLYCOSURIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MICE; MICE, INBRED ICR; NIACINAMIDE; PANCREAS; VITAMIN B COMPLEX;

MUS;

EID: 58149119432     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1087167     Document Type: Article

References (25)

1. Srinivasan K, Ramarao P. Animal models in type 2 diabetes research: an overview. Indian J Med Res 2007; 125: 451-472
2. Ladriere L, Malaisse-Lagae F, Fuhlendorff J, Malaisse WJ. Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats. Eur J Pharmacol 1997; 335: 227-234
3. Efanov AM, Appelskog IB, Abdel-Halim SM, Khan A, Branstrom R, Larsson O, Ostenson CG, Mest HJ, Berggren PO, Efendic S, Zaitsev SV. Insulinotropic activity of the imidazoline derivative RX871024 in the diabetic GK rats. Am J Physiol 2002; 282: E117-E124
4. Portha B, Serradas P. Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin. Am J Med 1991; 90: 15S-21S
5. Ikenoue T, Okazaki K, Fujitani S, Tsuchiya Y, Akiyoshi M, Maki T, Kondo N. Effect of a new hypoglycemic agent, A-4166 [(-)-N-(trans-4- isopropylcyclohexane-carbonyl)-D-phynylalanine], on postprandial blood glucose excursion: comparison with voglibose and glibenclamide. Biol Pharma Bull 1997; 20: 354-359
6. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42: 1324-1331
7. Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002; 51: 1461-1469
8. Mine T, Miura K, Kitahara Y, Okano A, Kawamori R. Nateglinide suppresses postprandial hypertriglyceridemia in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. Biol Pharma Bull 2002; 25: 1412-1416
9. Farrar NS, Chambers NJ, Carlsson AR, Denyer G, Johnston GA. Effect of a series of novel sulphonylthioureas on glucose tolerance in the obese fa/fa Zucker rat. Clin Exp Pharmacol Physiol 2001; 28: 386-391
10. Pieper AA, Brat DJ, Krug DK, Watkins CC, Gupta A, Blackshaw S, Verma A, Wang ZQ, Snyder SH. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci USA 1999; 96: 3059-3064
11. Burkart V, Wang ZQ, Radons J, Heller B, Herceg Z, Stingl L, Wagner EF, Kolb H. Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozotocin. Nature Med 1999; 5: 314-319
12. Shima K, Hirota M, Sato M, Numoto S, Oshima I. Effect of poly(ADP-ribose) synthetase inhibitor administration to streptozotocin-induced diabetic rats on insulin and glucagon contents in their pancreas. Diabetes Res Clin Pract 1987; 3: 135-142
13. Oguri S, Motegi K, Endo Y. Augmented lipopolysaccharide-induction of the histamine-forming enzyme in streptozotocin-induced diabetic mice. Biochim Biophys Acta 2003; 1637: 83-90
14. LeDoux SP, Hall CR, Forbes PM, Patton NJ, Wilson GL. Mechanisms of nicotinamide and thymidine protection from alloxan and streptozotocin toxicity. Diabetes 1988; 37: 1015-1019
15. Masiello P, Broca C, Gross R, Roye M, Manteghetti M, Hillaire-Buys D, Novelli M, Ribes G. Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide. Diabetes 1998; 47: 224-229
16. Ichikawa K, Yamato T, Ojima K, Tsuji A, Ishikawa K, Kusama H, Kojima M. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2002; 29: 423-427
17. Berthiaume N, Zinker BA. Metabolic responses in a model of insulin resistance: Comparison between oral glucose and meal tolerance tests. Metabolism 2002; 51: 595-598
18. Like AA, Rossini AA. Streptozotocin-induced pancreatic insulitis: new model of diabetes mellitus. Science 1976; 193: 415-417
19. Casirola DM, Ferraris RP. α-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice. Metabolism 2006; 55: 832-841
20. Matsuo T, Odaka H, Ikeda H. Effect of an intestinal disaccharidase inhibitor (AO-128) on obesity and diabetes. Am J Clin Nutr 1992; 55: 314S-317S
21. y. J Nutr Sci Vitaminol 1992; 38: 27-37
22. Azuma K, Toyofuku Y, Iesaki T, Otsuka A, Tanaka A, Mita T, Hirose T, Tanaka Y, Daida H, Kawamori R, Watada H. Acarbose, an alpha-glucosidase inhibitor, improves endothelial dysfunction in Goto-Kakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res Commun 2006; 345: 688-693
23. Cheng JT, Huang CC, Liu IM, Tzeng TF, Chang CJ. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes 2006; 55: 819-825
24. El-Atat F, MacFarlane SI, Sowers JR. Diabetes, hypertension, and cardiovascular derangements: pathophysiology and management. Curr Hypertens Rep 2004; 6: 215-223
25. Santeusanio F, Loreto C Di, Lucidi P, Murdolo G, De Cicco A, Parlanti N, Piccioni F, De Feo P. Diabetes and exercise. J Endocrinol Invest 2003; 26: 937-940